MAIA Biotechnology Highlights Efficacy Data From Phase 2 Clinical Trial, THIO-101, Evaluating Ateganosine Sequenced With Immune CPI Cemiplimab In Patients With Advanced NSCLC

MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today highlighted positive efficacy data from its Phase 2 clinical trial, THIO-101, evaluating ateganosine (THIO) sequenced with the immune checkpoint inhibitor (CPI) cemiplimab (Libtayo®) in patients with advanced non-small cell lung cancer (NSCLC) who had failed two or more standard-of-care therapy regimens.

As of June 30, 2025,

• Estimated median progression free survival (PFS) in third-line treatment (180 mg dose) was 5.6 months. The comparable PFS threshold in standard of care treatments is 2.5 months1.
• Estimated median overall survival (OS) was 17.8 months, with a 95% confidence interval (CI) lower bound of 12.5 months and a 99% CI lower bound of 10.8 months, consistent with the prior data readout (May 15, 2025).
• Across patients of all treatment lines, 2 patients have completed 33 cycles of therapy, highlighting ateganosine' potential for extended dosing, which usually translates into longer patient survival.